PRKN and diabetic cardiomyopathy: Similarly, the PINK1‐Parkin pathway is suppressed in diabetic cardiomyopathy, a defect that can be therapeutically targeted by agents such as canagliflozin, which activates Parkin‐dependent mitophagy to alleviate cardiac dysfunction [286].